Views: 33 Author: Site Editor Publish Time: 2023-04-17 Origin: Site
China is one of the main sources of pharmaceutical intermediates manufacturers in the world. In recent years, Chinese pharmaceutical intermediate manufacturers have been playing an increasingly important role in the global market, and their market scale and technological level have been improving.
First, China has a large number of pharmaceutical intermediate manufacturers, spread across the country. Among them, Jiangsu, Zhejiang, Shandong, Hebei and other places are mainly concentrated areas. These producers range in size from small to large, from those engaged in the production of specific types of intermediates to those engaged in the production of multiple types of intermediates. The competition among these producers is fierce, the market share is unevenly distributed, and the large enterprises occupy the dominant position of the market.
Second, China's pharmaceutical intermediate manufacturers are also improving in terms of technology. They continue to innovate in chemical synthesis, production process, production equipment and so on to improve product quality and production efficiency. At the same time, the state has also strengthened the supervision of the production of medical intermediates, and carried out strict management and supervision on environmental pollution and production safety.
Finally, Chinese pharmaceutical intermediate manufacturers also have certain competitive advantages in the global market. Due to its technical level and cost advantage, Chinese pharmaceutical intermediates manufacturers have certain competitiveness in the international market, and more and more international enterprises choose to purchase pharmaceutical intermediates from China.
At the same time, Chinese pharmaceutical intermediate manufacturers also actively expand the international market, strengthen cooperation with the international market, improve brand awareness and international influence.
Market size: China's pharmaceutical intermediates market is huge, reaching about 483 billion yuan in 2019, accounting for nearly 40% of the global pharmaceutical intermediates market share.
Product category: Chinese pharmaceutical intermediates manufacturers cover a wide range of product categories, from basic chemicals to high-end specialty intermediates, such as amino acids, vitamins, antibiotics, etc.
International market share: China's export volume of pharmaceutical intermediates continues to increase, reaching $142.5 billion in 2019, accounting for most of the global export market share of pharmaceutical intermediates.
Manufacturing cost advantage: Pharmaceutical intermediates manufacturers in China have lower production costs due to the local cheap labor, raw material supply chain and low-cost factory facilities.
Technology development: With the continuous improvement of technology, China's pharmaceutical intermediate manufacturers are gradually transforming to high-end technology and high value-added products. At the same time, they also pay attention to environmental protection and sustainable development, and constantly promote green production.
Firstly, China has a large and well-established pharmaceutical industry, with many experienced manufacturers that produce high-quality intermediates. This has resulted in a competitive market that drives down costs, making it more affordable for businesses to source intermediates from China.
Secondly, China has a vast pool of skilled labor that is capable of producing complex intermediates. This is due to the country's strong emphasis on education and training, which has led to the development of a highly skilled workforce.
Thirdly, China has a favorable regulatory environment for the pharmaceutical industry, with a well-established regulatory framework and government support for the industry's growth. This ensures that manufacturers in China meet international quality standards, making them a reliable source of intermediates.
Fourthly, Chinese pharmaceutical intermediate manufacturers are usually flexible in responding to changes in external demand, and can customize production according to the specific needs of customers. At the same time, they can also quickly adjust the output to adapt to changes in market demand. Moreover, many Chinese pharmaceutical intermediate manufacturers have passed the certification of international quality standards, such as the EU GMP certification and the US FDA certification. It shows that they pay attention to quality control and product safety in the production process.
Lastly, China's geographical location also makes it an attractive option for businesses. It is strategically located in Asia, making it a gateway to other markets in the region. This makes it easier and more cost-effective for businesses to transport intermediates to other parts of the world, reducing transportation costs and lead times.
Ningbo Nuobai Pharmaceutical Co., Ltd. was formerly known as Ninhua Group Pharmaceutical Business Division (started in 1987 as a part-time Vice President unit of China Chamber of Commerce of Medicines & Health Products Importers & Exporters). In 2017, after completing the third reform, the Group established Ningbo Nuobai Pharmaceutical Co., Ltd, i.e. a subsidiary of Zhejiang Langhua Pharmaceutical Co., Ltd. specializing in the import and export of pharmaceutical products.
With more than 30 years of international operation, the Company has set up a strong and perfect supplier network and overseas sales platform. Its business covers the fields of fine chemicals, pharmaceutical intermediates, bulk drugs, western pharmaceutical preparations and medical consumables and devices, and its products are sold all over the world. Its brand SINING also enjoys high reputation in Africa, Southeast Asia, South America and other international markets.
The Company has always been market-oriented and focused on customer satisfaction. While ensuring reliable, stable supply and cost-effective products, it strives to create value for customers by providing professional compliance solutions such as supply chain management, due diligence, third-party audit, GMP and EHS training and promotion, and drug registration at home and abroad.
Due to its high-quality products and services, the Company was selected as one of “Top 100 Pharmaceutical Internationalized Enterprises - Quality Suppliers and Partners in the International Market” by China Chamber of Commerce of Medicines & Health Products Importers & Exporters in 2019.